ZEO ScientifiX IncOTCQB:ZEOX
- LAST PRICE1.3000
- TODAY'S CHANGE (%)0.0500 (4.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close1.3000 / 1.2500
- Day Range
- 52 Week Range
- Volume5,944
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZEOX |
|---|---|---|
| 09:32 ET | 188 | 1.3 |
| 10:06 ET | 2200 | 1.25 |
| 10:08 ET | 1500 | 1.25 |
| 11:44 ET | 1000 | 1.5 |
| 01:21 ET | 1000 | 1.3 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ZEO ScientifiX Inc | 8.0M | -1.6x | --- |
CLSTV Corp | 6.6M | 0.0x | --- |
HealthWarehouse.com Inc | 6.5M | -3.1x | --- |
Amexdrug Corp | 355.8K | 1.3x | +16.89% |
BIMI Holdings Inc | 16.7M | 0.9x | --- |
Progressive Care Inc | 11.0M | -0.5x | --- |
Company Information
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Company’s product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patient’s own peripheral blood.
Contact Information
- Headquarters
- 3321 College Avenue, Suite 246DAVIE, FL, United States 33328
- Phone
- 305-370-0482
- Fax
- ---
Executives
- Chief Executive Officer, Director
- Harry Leider
- Independent Non-Executive Vice Chairman of the Board
- Chuck Bretz
- Chief Financial Officer, Director
- Ian Bothwell
- Executive Vice President, Chief Scientific Officer
- Howard Golub
- Chief Medical Officer, Director
- George Shapiro
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.0M |
|---|---|
Revenue (TTM) | $4.6M |
Shares Outstanding | 6.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 4.48 |
EPS | $-0.82 |
Book Value | $-0.17 |
P/E Ratio | -1.6x |
Price/Sales (TTM) | 1.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -126.08% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
